This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
antibiotic resistance | 367 |
antibiotic use | 303 |
united states | 226 |
acute bronchitis | 221 |
antimicrobial resistance | 206 |
respiratory tract | 189 |
acquired pneumonia | 188 |
infectious diseases | 188 |
public health | 178 |
antibiotic therapy | 164 |
primary care | 156 |
antibiotic treatment | 131 |
tract infections | 130 |
antibiotic prescribing | 119 |
staphylococcus aureus | 113 |
resistance genes | 106 |
health care | 93 |
escherichia coli | 92 |
resistant bacteria | 89 |
respiratory infections | 89 |
otitis media | 87 |
streptococcus pneumoniae | 86 |
upper respiratory | 84 |
risk factors | 83 |
systematic review | 81 |
infectious disease | 79 |
gut microbiota | 77 |
controlled trial | 73 |
human health | 72 |
sore throat | 67 |
animal health | 66 |
acute respiratory | 66 |
antimicrobial agents | 64 |
drug resistance | 64 |
helicobacter pylori | 63 |
urinary tract | 63 |
one health | 61 |
tract infection | 60 |
antimicrobial stewardship | 60 |
antibiotic prescription | 59 |
new antibiotics | 58 |
randomized controlled | 56 |
clinical practice | 55 |
doc id | 53 |
cord uid | 53 |
lower respiratory | 51 |
hospitalized patients | 51 |
antimicrobial therapy | 51 |
streptococcal pharyngitis | 51 |
clostridium difficile | 50 |
clinical trials | 49 |
cell wall | 49 |
may also | 48 |
negative bacteria | 48 |
bacterial infections | 47 |
intravenous antibiotics | 46 |
pseudomonas aeruginosa | 44 |
resistant staphylococcus | 44 |
chronic bronchitis | 42 |
wastewater treatment | 42 |
controlled trials | 42 |
resistant strains | 40 |
blood cultures | 40 |
common cold | 40 |
antibiotic prescriptions | 40 |
severe cap | 40 |
among patients | 39 |
infection prevention | 39 |
mg kg | 39 |
neutropenic patients | 39 |
world health | 38 |
haemophilus influenzae | 37 |
mycoplasma pneumoniae | 37 |
bacterial infection | 37 |
infection control | 37 |
positive bacteria | 37 |
global health | 35 |
bacterial pathogens | 35 |
infections caused | 35 |
antimicrobial use | 35 |
diagnostic testing | 34 |
climate change | 34 |
side effects | 34 |
antibiotic stewardship | 34 |
syncytial virus | 34 |
respiratory syncytial | 34 |
pylori eradication | 34 |
diseases society | 34 |
veterinary medicine | 34 |
spectrum antibiotics | 33 |
pneumococcal pneumonia | 33 |
appropriate antibiotic | 33 |
septic shock | 33 |
natural products | 33 |
intensive care | 33 |
recent years | 32 |
emergency department | 32 |
see scheme | 32 |
critically ill | 32 |
adult patients | 32 |
resistant organisms | 32 |
practice guidelines | 32 |
lactam antibiotics | 32 |
broad spectrum | 32 |
viral infections | 31 |
randomized trial | 31 |
influenza virus | 31 |
health organization | 31 |
clinical trial | 31 |
acute otitis | 31 |
immune system | 31 |
antibiotic redosing | 31 |
respiratory viruses | 31 |
hand hygiene | 31 |
physical examination | 30 |
adverse effects | 30 |
bacterial pneumonia | 30 |
diagnostic tests | 30 |
medically important | 30 |
control group | 30 |
gram stain | 30 |
gastric cancer | 30 |
protein synthesis | 30 |
fungal infections | 29 |
antibiotic consumption | 29 |
food animals | 29 |
preventive approaches | 29 |
social norms | 29 |
ill patients | 29 |
lyme disease | 28 |
oral therapy | 28 |
new antibiotic | 28 |
inappropriate antibiotic | 28 |
per year | 28 |
bacterial cell | 27 |
gut microbiome | 27 |
acute sinusitis | 27 |
rapid antigen | 27 |
culture results | 27 |
sputum production | 27 |
antigen detection | 27 |
pulmonary disease | 27 |
disease control | 27 |
resistance mechanisms | 27 |
drug targets | 26 |
time pcr | 26 |
developing countries | 26 |
mortality rate | 26 |
gp staff | 26 |
oral antibiotics | 26 |
bacterial resistance | 25 |
cohort study | 25 |
drinking water | 25 |
klebsiella pneumoniae | 25 |
respiratory infection | 25 |
hospital admission | 25 |
antimicrobial drugs | 25 |
negative bacilli | 25 |
animal production | 25 |
statistically significant | 24 |
antibiotics may | 24 |
care physicians | 24 |
macrolide resistance | 24 |
resistance gene | 24 |
immunocompromised patients | 24 |
antiproliferative activity | 24 |
intervention group | 24 |
intraoperative antibiotic | 24 |
gene transfer | 24 |
pathogenic bacteria | 24 |
antibacterial activity | 24 |
urinary antigen | 24 |
drug resistant | 23 |
income countries | 23 |
increased risk | 23 |
treatment failure | 23 |
strong recommendation | 23 |
cancer patients | 23 |
high risk | 23 |
susceptibility testing | 23 |
intravenous antibiotic | 23 |
bacterial species | 23 |
patients treated | 23 |
difficile infection | 23 |
commonly used | 22 |
even though | 22 |
past years | 22 |
pneumococcal disease | 22 |
western pacific | 22 |
unnecessary antibiotic | 22 |
adverse events | 22 |
treatment plants | 22 |
soft tissue | 22 |
pacific region | 22 |
general practice | 22 |
initial visit | 21 |
nasal discharge | 21 |
herpes simplex | 21 |
medical care | 21 |
antibiotic regimen | 21 |
cell death | 21 |
amino group | 21 |
combination treatment | 21 |
producing animals | 21 |
streptococcus pyogenes | 21 |
risk patients | 21 |
million people | 21 |
streptococcal infection | 21 |
day course | 21 |
resistant pathogens | 21 |
acute pharyngitis | 21 |
rheumatic fever | 21 |
effect size | 21 |
resistance among | 21 |
blood culture | 21 |
drug discovery | 21 |
respiratory syndrome | 20 |
virus infection | 20 |
hospital wastewater | 20 |
pharmaceutical industry | 20 |
one study | 20 |
times daily | 20 |
invasive fungal | 20 |
combination therapy | 20 |
animal feed | 20 |
single dose | 20 |
chain reaction | 20 |
antifungal activity | 20 |
severe pneumonia | 20 |
outer membrane | 20 |
bacterial strains | 20 |
febrile neutropenic | 20 |
chronic obstructive | 20 |
clinical features | 20 |
action plan | 20 |
care unit | 20 |
acute bacterial | 19 |
decision support | 19 |
antibiotic resistant | 19 |
bone marrow | 19 |
result group | 19 |
communityacquired pneumonia | 19 |
streptococcal pharyngotonsillitis | 19 |
prescription rate | 19 |
pneumococcal conjugate | 19 |
genetic elements | 19 |
antibacterial agents | 19 |
microbial communities | 19 |
cell lines | 19 |
drug administration | 19 |
generation cephalosporin | 19 |
antimicrobial treatment | 19 |
antibiotic dose | 19 |
invasive pneumococcal | 19 |
prescribe antibiotics | 19 |
resistant enterococci | 19 |
randomised controlled | 19 |
antimicrobial prescribing | 19 |
pylori infection | 19 |
icu patients | 19 |
polymerase chain | 19 |
treatment guidelines | 19 |
antimicrobial susceptibility | 18 |
drug use | 18 |
antibiotic usage | 18 |
strep throat | 18 |
chest radiograph | 18 |
empiric antibiotic | 18 |
clinically relevant | 18 |
acute cough | 18 |
resistance patterns | 18 |
obstructive pulmonary | 18 |
antibiotics used | 18 |
generation cephalosporins | 18 |
bite wounds | 18 |
oral antibiotic | 18 |
severe community | 18 |
treat strategy | 18 |
patients hospitalized | 18 |
moderate recommendation | 18 |
twice daily | 18 |
hiv aids | 18 |
antibiotic susceptibility | 18 |
common cause | 18 |
active site | 18 |
using antibiotics | 18 |
kill bacteria | 18 |
biological activity | 18 |
minor criteria | 17 |
nucleic acid | 17 |
antifungal therapy | 17 |
empirical antibiotic | 17 |
industrial vets | 17 |
another study | 17 |
economic model | 17 |
patients receiving | 17 |
patient care | 17 |
prospective study | 17 |
important role | 17 |
mg ml | 17 |
may help | 17 |
conjugate vaccine | 17 |
level iii | 17 |
elderly patients | 17 |
veterinary profession | 17 |
severe acute | 17 |
everyday life | 17 |
acute exacerbations | 17 |
emerging infectious | 17 |
multidrug resistance | 17 |
viral infection | 17 |
lung disease | 17 |
susceptibility tests | 17 |
randomized clinical | 17 |
medical center | 17 |
severe sepsis | 17 |
professional expertise | 17 |
diagnostic tool | 17 |
childhood pneumonia | 17 |
risk assessment | 17 |
west nile | 17 |
iii evidence | 17 |
infective endocarditis | 17 |
community acquired | 17 |
amr problem | 17 |
human gut | 16 |
multidrug resistant | 16 |
therapeutic use | 16 |
chlamydia pneumoniae | 16 |
children aged | 16 |
initial antibiotic | 16 |
older adults | 16 |
resistant infections | 16 |
clinical prediction | 16 |
sexually transmitted | 16 |
vaginal discharge | 16 |
recent study | 16 |
united kingdom | 16 |
associated infections | 16 |
growth promotion | 16 |
associated pneumonia | 16 |
positive blood | 16 |
effl ux | 16 |
innate immunity | 16 |
received antibiotics | 16 |
natural ecosystems | 16 |
innate immune | 16 |
qualitative study | 16 |
antibiotics kill | 15 |
acute leukemia | 15 |
level ii | 15 |
throat culture | 15 |
respiratory pathogens | 15 |
empirical therapy | 15 |
small intestine | 15 |
diabetic foot | 15 |
infl uenza | 15 |
negative pathogens | 15 |
patient safety | 15 |
american academy | 15 |
rapid result | 15 |
thoracic society | 15 |
respiratory illness | 15 |
detection test | 15 |
several studies | 15 |
food animal | 15 |
level i | 15 |
urine dipsticks | 15 |
may lead | 15 |
evidence base | 15 |
clinical outcomes | 15 |
reducing antibiotic | 15 |
recurrent uti | 15 |
calf diarrhea | 15 |
host cell | 15 |
wide range | 15 |
admission decision | 15 |
atypical pathogens | 15 |
patients without | 15 |
antibiotic exposure | 15 |
hiv infection | 15 |
less common | 15 |
prescribed antibiotics | 15 |
fecal microbiota | 15 |
patients may | 15 |
focus group | 15 |
influenza vaccine | 15 |
reactive protein | 15 |
pharmaceutical companies | 14 |
polysaccharide vaccine | 14 |
i evidence | 14 |
bacterial rhinosinusitis | 14 |
neuraminidase inhibitors | 14 |
resistant genes | 14 |
controlled study | 14 |
prescribing antibiotics | 14 |
acute exacerbation | 14 |
large number | 14 |
allergic patients | 14 |
avian influenza | 14 |
medical students | 14 |
heavy metals | 14 |
selective pressure | 14 |
icu admission | 14 |
antibiotic administration | 14 |
risk factor | 14 |
hospital stay | 14 |
fungal species | 14 |
outpatient setting | 14 |
north america | 14 |
clinical diagnosis | 14 |
nile virus | 14 |
use antibiotics | 14 |
skin infections | 14 |
acute rhinosinusitis | 14 |
antibiotic prophylaxis | 14 |
tumour cell | 14 |
without antibiotics | 14 |
teicoplanin aglycone | 14 |
care facilities | 14 |
moraxella catarrhalis | 14 |
low risk | 14 |
samples collected | 14 |
bloodstream infections | 14 |
positive cocci | 14 |
treatment options | 14 |
resistant bacterial | 14 |
amino acids | 14 |
respiratory fluoroquinolone | 14 |
mrsa clones | 14 |
ii evidence | 14 |
bacterial populations | 14 |
resistant gram | 14 |
bactericidal activity | 14 |
associated diarrhea | 14 |
study group | 14 |
multiplex pcr | 14 |
dose amoxicillin | 13 |
mp pneumonia | 13 |
antimicrobial peptides | 13 |
three times | 13 |
different types | 13 |
within hours | 13 |
pregnant women | 13 |
resistance determinants | 13 |
years ago | 13 |
least one | 13 |
animal agriculture | 13 |
per day | 13 |
influenzae type | 13 |
cell division | 13 |
asian countries | 13 |
among children | 13 |
antitumour activity | 13 |
mortality rates | 13 |
will also | 13 |
bacteremic pneumococcal | 13 |
horizontal gene | 13 |
inappropriate use | 13 |
patients admitted | 13 |
developed countries | 13 |
outcome measure | 13 |
clinical decision | 13 |
see table | 13 |
cap guidelines | 13 |
study design | 13 |
clavulanic acid | 13 |
clinical development | 13 |
mycobacterium tuberculosis | 13 |
immune response | 13 |
judicious use | 13 |
surgical site | 13 |
human medicine | 13 |
glycopeptide antibiotics | 13 |
clinical isolates | 13 |
reduce antibiotic | 13 |
spectrum antibiotic | 13 |
positive strain | 13 |
pneumococcal polysaccharide | 13 |
differential diagnosis | 13 |
factors associated | 13 |
groups reported | 13 |
antigen tests | 13 |
drug sales | 13 |
sputum culture | 12 |
updated diagnostic | 12 |
health system | 12 |
hematological malignancies | 12 |
inhibitory activity | 12 |
routine real | 12 |
based drug | 12 |
guide antibiotic | 12 |
also important | 12 |
within days | 12 |
primary health | 12 |
naturally occurring | 12 |
clinical findings | 12 |
significant reduction | 12 |
dental antibiotic | 12 |
patient satisfaction | 12 |
general population | 12 |
etiologic diagnosis | 12 |
legionella species | 12 |
antibiotic resistome | 12 |
among adults | 12 |
spectrum beta | 12 |
empiric therapy | 12 |
stewardship program | 12 |
respiratory distress | 12 |
colistin resistance | 12 |
resistant streptococcus | 12 |
chemical modification | 12 |
genome sequencing | 12 |
treatment plant | 12 |
oral amoxicillin | 12 |
initial therapy | 12 |
urine samples | 12 |
cochrane review | 12 |
enterococcus faecium | 12 |
middle ear | 12 |
recent studies | 12 |
aged years | 12 |
poultry vets | 12 |
livestock farming | 12 |
topoisomerase i | 12 |
approximately one | 12 |
new york | 12 |
antibiotic regimens | 12 |
stem cell | 12 |
antifungal drugs | 12 |
line treatment | 12 |
infectious mononucleosis | 12 |
suppurative complications | 12 |
intestinal tract | 12 |
starting antibiotic | 12 |
different antibiotics | 12 |
previous studies | 12 |
bacterial growth | 12 |
clinical stability | 12 |
eradication therapy | 12 |
human immunodeficiency | 12 |
st century | 12 |
uncomplicated acute | 12 |
anaerobic bacteria | 12 |
new delhi | 12 |
chronic rhinosinusitis | 12 |
widely used | 12 |
otherwise healthy | 12 |
also known | 12 |
decision making | 12 |
short course | 12 |
delayed result | 12 |
pneumococcal bacteremia | 12 |
respiratory failure | 12 |
leading cause | 12 |
randomized trials | 12 |
diagnostic procedures | 12 |
supply chain | 11 |
blood pressure | 11 |
important antibiotics | 11 |
acinetobacter baumannii | 11 |
two decades | 11 |
many patients | 11 |
parainfluenza virus | 11 |
minimum inhibitory | 11 |
paranasal sinuses | 11 |
used antibiotics | 11 |
inhibitory concentration | 11 |
american thoracic | 11 |
plus amikacin | 11 |
synthetic derivatives | 11 |
world bank | 11 |
global action | 11 |
clinical use | 11 |
may cause | 11 |
increasing resistance | 11 |
pulmonary infiltrates | 11 |
vancomycin resistance | 11 |
influenza vaccination | 11 |
viral hepatitis | 11 |
urine culture | 11 |
amino acid | 11 |
viral respiratory | 11 |
least days | 11 |
significant differences | 11 |
mortality among | 11 |
daily practice | 11 |
outpatient treatment | 11 |
high rates | 11 |
many countries | 11 |
abdominal pain | 11 |
rapid diagnostic | 11 |
middle east | 11 |
line agents | 11 |
fungal infection | 11 |
healthcare settings | 11 |
transplant recipients | 11 |
new drugs | 11 |
compliance rates | 11 |
resistance rates | 11 |
drotrecogin alfa | 11 |
microbiota transplantation | 11 |
observational study | 11 |
treatment failures | 11 |
antibiotic discovery | 11 |
gold standard | 11 |
unnecessary use | 11 |
important antimicrobials | 11 |
antibacterial drug | 11 |
practice guideline | 11 |
paediatric patients | 11 |
health problem | 11 |
respiratory virus | 11 |
airway obstruction | 11 |
livestock production | 11 |
tissue infections | 11 |
invasive aspergillosis | 11 |
ambulatory care | 11 |
immune responses | 11 |
respiratory panel | 11 |
family physicians | 11 |
viridans streptococci | 11 |
nervous system | 11 |
legionnaires disease | 11 |
i think | 11 |
young children | 11 |
documented infection | 11 |
billion per | 11 |
primary outcome | 11 |
serious infections | 11 |
outpatient antibiotic | 10 |
may provide | 10 |
significantly increased | 10 |
widespread use | 10 |
year period | 10 |
policy makers | 10 |
logistic regression | 10 |
life expectancy | 10 |
committee members | 10 |
coli strains | 10 |
antibiotic management | 10 |
virulence factors | 10 |
health services | 10 |
purulent sputum | 10 |
risk reduction | 10 |
secondary education | 10 |
resistant enterobacteriaceae | 10 |
major cause | 10 |
food safety | 10 |
national guidance | 10 |
clinical presentation | 10 |
resistance development | 10 |
cystic fibrosis | 10 |
heart failure | 10 |
zoonotic diseases | 10 |
trimethoprim sulfamethoxazole | 10 |
infection may | 10 |
electronic medical | 10 |
patient outcomes | 10 |
producing enterobacteriaceae | 10 |
atp synthase | 10 |
prediction models | 10 |
antiviral medications | 10 |
appropriate treatment | 10 |
septic arthritis | 10 |
mobile genetic | 10 |
data analysis | 10 |
precision public | 10 |
disease prevention | 10 |
molecular characterization | 10 |
twentieth century | 10 |
rapid diagnosis | 10 |
bordetella pertussis | 10 |
staff reported | 10 |
horizontal transfer | 10 |
liver disease | 10 |
granulocytopenic patients | 10 |
summary effect | 10 |
less effective | 10 |
milk replacer | 10 |
may require | 10 |
productive cough | 10 |
drug therapy | 10 |
ambulatory medical | 10 |
hospital effluents | 10 |
lymph nodes | 10 |
controlled studies | 10 |
indirect costs | 10 |
i will | 10 |
first time | 10 |
antibiotic action | 10 |
influenza viruses | 10 |
anterior cervical | 10 |
individual patient | 10 |
care clinics | 10 |
new drug | 10 |
throat swab | 10 |
molecular basis | 10 |
national institute | 10 |
filmarray respiratory | 10 |
vital signs | 10 |
veterinary services | 10 |
immunodeficiency virus | 10 |
barr virus | 10 |
usually caused | 10 |
task force | 10 |
enzyme inhibitors | 10 |
will likely | 10 |
acquired respiratory | 10 |
wide variety | 10 |
suspected uti | 10 |
standard deviation | 10 |
viral etiology | 10 |
economic impact | 10 |
three days | 10 |
high mortality | 10 |
extended spectrum | 10 |
may include | 10 |
high fever | 10 |
infection caused | 10 |
disease caused | 10 |
prescription rates | 10 |
working group | 9 |
renal function | 9 |
advisory committee | 9 |
data suggest | 9 |
health issues | 9 |
shorter duration | 9 |
asthma exacerbations | 9 |
kg day | 9 |
bacterial sinusitis | 9 |
cell membrane | 9 |
various studies | 9 |
redosing guidelines | 9 |
healthy adults | 9 |
valent pneumococcal | 9 |
every hours | 9 |
pathogenic microbes | 9 |
selected patients | 9 |
causative agent | 9 |
pcr assays | 9 |
febrile neutropenia | 9 |
national strategy | 9 |
excessive antibiotic | 9 |
hong kong | 9 |
sexually active | 9 |
national action | 9 |
secondary metabolites | 9 |
antimicrobial drug | 9 |
one third | 9 |
better understanding | 9 |
viral load | 9 |
ascitic fluid | 9 |
clinical settings | 9 |
targeted hygiene | 9 |
diagnostic tools | 9 |
first antibiotic | 9 |
requiring hospitalization | 9 |
epithelial cells | 9 |
oral administration | 9 |
increased mortality | 9 |
resistance mechanism | 9 |
increasing antibiotic | 9 |
antibiotic recommendations | 9 |
high levels | 9 |
gause institute | 9 |
emerging pathogen | 9 |
better evidence | 9 |
intravenous therapy | 9 |
respiratory rate | 9 |
one example | 9 |
highly conserved | 9 |
drug users | 9 |
lower mortality | 9 |
last years | 9 |
surface water | 9 |
acute rheumatic | 9 |
comparative study | 9 |
costs associated | 9 |
cyclic carbonate | 9 |
veterinary expertise | 9 |
patients presenting | 9 |
high dose | 9 |
many cases | 9 |
new semi | 9 |
primary healthcare | 9 |
date palm | 9 |
antibiotics use | 9 |
anesthesia providers | 9 |
rapid tests | 9 |
production practices | 9 |
predictive value | 9 |
cytoplasmic membrane | 9 |
effective treatment | 9 |
quality improvement | 9 |
may occur | 9 |
without prescription | 9 |
leg ulcers | 9 |
neisseria gonorrhoeae | 9 |
vitro activity | 9 |
clinically documented | 9 |
european union | 9 |
line therapy | 9 |
near future | 9 |
human pathogens | 9 |
common causes | 9 |
like receptor | 9 |
severe infections | 9 |
sos response | 9 |
within weeks | 9 |
global burden | 9 |
systemic signs | 9 |
sore throats | 9 |
pneumoniae infection | 9 |
disease society | 9 |
dna duplex | 9 |
study participants | 9 |
new guidelines | 9 |
orbital cellulitis | 9 |
economic development | 9 |
diagnostic process | 9 |
recently received | 9 |
care centers | 9 |
test result | 9 |
hbv infection | 9 |
resistant isolates | 9 |
european countries | 9 |
bacterial peritonitis | 9 |
hcv infection | 9 |
among hospitalized | 9 |
may result | 9 |
wbc count | 9 |
bacterial causes | 9 |
environmental health | 9 |
environmental bacteria | 9 |
appropriate use | 9 |
clinical efficacy | 9 |
coliform bacteria | 9 |
infections due | 9 |
transmitted diseases | 9 |
mechanical ventilation | 9 |
antigen test | 9 |
drug market | 9 |
peritonsillar abscess | 9 |
rna polymerase | 9 |
emerging pathogens | 9 |
virus infections | 9 |
vast majority | 9 |
typical symptoms | 9 |
healthy patients | 9 |
medical record | 9 |
care physician | 9 |
alfa activated | 9 |
care survey | 9 |
prophylactic antibiotics | 9 |
respiratory disease | 9 |
binding proteins | 9 |
human beings | 9 |
clinical studies | 9 |
acute tonsillitis | 9 |
active surveillance | 9 |
underlying disease | 9 |
asymptomatic bacteriuria | 9 |
south korea | 9 |
tomographic scan | 9 |
literature review | 9 |
macrolide antibiotics | 9 |
life settings | 9 |
conjugate vaccines | 9 |
stewardship programs | 8 |
national guidelines | 8 |
bactericidal antibiotics | 8 |
blind trial | 8 |
economic outcomes | 8 |
centor criteria | 8 |
super wicked | 8 |
political economy | 8 |
antibacterial discovery | 8 |
compliance rate | 8 |
highly resistant | 8 |
infectious agents | 8 |
line antibiotics | 8 |
national institutes | 8 |
teaching hospital | 8 |
health department | 8 |
age group | 8 |
community settings | 8 |
immune cells | 8 |
improved treatment | 8 |
include fever | 8 |
healthcare system | 8 |
age years | 8 |
care workers | 8 |
also showed | 8 |
us billion | 8 |
reported cases | 8 |
years old | 8 |
distress syndrome | 8 |
family members | 8 |
teichoic acids | 8 |
empirical treatment | 8 |
two different | 8 |
respiratory viral | 8 |
critically important | 8 |
global warming | 8 |
supplementary material | 8 |
well documented | 8 |
scoring system | 8 |
pulmonary aspergillosis | 8 |
cranberry juice | 8 |
spontaneous bacterial | 8 |
natural antibiotics | 8 |
direct costs | 8 |
observational studies | 8 |
excessive use | 8 |
little evidence | 8 |
assisted tomographic | 8 |
causative organism | 8 |
legionella pneumophila | 8 |
aecb episodes | 8 |
anthracycline antibiotics | 8 |
general practitioners | 8 |
healthcare providers | 8 |
drug development | 8 |
prior antibiotic | 8 |
delayed prescription | 8 |
resistant escherichia | 8 |
common infections | 8 |
two major | 8 |
antibiotic overuse | 8 |
infections may | 8 |
determine whether | 8 |
computed tomography | 8 |
new generation | 8 |
animal drug | 8 |
two drugs | 8 |
many people | 8 |
ulcer disease | 8 |
five years | 8 |
contaminated water | 8 |
severe illness | 8 |
macrolide antibiotic | 8 |
readily available | 8 |
candida albicans | 8 |
like illness | 8 |
particularly relevant | 8 |
case report | 8 |
various antibiotics | 8 |
systematic reviews | 8 |
significant benefit | 8 |
day care | 8 |
significantly decreased | 8 |
blood agar | 8 |
general medical | 8 |
host immune | 8 |
first hours | 8 |
new class | 8 |
borne diseases | 8 |
disease among | 8 |
human microbiome | 8 |
delhi metallo | 8 |
clinical signs | 8 |
thereby reducing | 8 |
surveillance system | 8 |
takes place | 8 |
patients diagnosed | 8 |
hospitalized adults | 8 |
milk replacers | 8 |
crp level | 8 |
mg twice | 8 |
also found | 8 |
scientific evidence | 8 |
antiviral activity | 8 |
national ambulatory | 8 |
uti leaflet | 8 |
ap caused | 8 |
prediction rule | 8 |
sputum cultures | 8 |
farm animal | 8 |
catalytic mechanism | 8 |
empiric antibiotics | 8 |
bactericidal effect | 8 |
president obama | 8 |
antibiotic selection | 8 |
among bacteria | 8 |
bloodstream infection | 8 |
healthcare facilities | 8 |
new chemical | 8 |
simplex virus | 8 |
control strategies | 8 |
children less | 8 |
necrotizing enterocolitis | 8 |
psi score | 8 |
data collection | 8 |
will require | 8 |
central nervous | 8 |
chronic infection | 8 |
treat infections | 8 |
bal fluids | 8 |
initial treatment | 8 |
suspected infection | 8 |
secondary bacterial | 8 |
common reason | 8 |
bacterial counts | 8 |
organ transplants | 8 |
food chain | 8 |
new technologies | 8 |
exclusion criteria | 8 |
emergency room | 8 |
common respiratory | 8 |
mental status | 8 |
bacterial meningitis | 8 |
large proportion | 8 |
also reported | 8 |
antibiotic development | 8 |
focus groups | 8 |
heart disease | 8 |
time frame | 8 |
viral pneumonia | 8 |
cost savings | 8 |
common bacterial | 8 |
nasal cavity | 8 |
neutropenic patient | 8 |
site infection | 8 |
severe asthma | 8 |
less likely | 8 |
resistant streptococci | 8 |
influenza infection | 8 |
human adenovirus | 8 |
medical community | 8 |
cervical lymph | 8 |
may contribute | 8 |
viral pathogens | 8 |
comorbid conditions | 8 |
health risks | 8 |
antibiotic concentrations | 8 |
selection pressure | 8 |
clinical score | 8 |
among different | 8 |
million units | 8 |
bacterial communities | 8 |
ar spread | 8 |
existing antibiotics | 8 |
multiple antibiotic | 8 |
antimicrobial agent | 8 |
patient expectations | 8 |
long time | 8 |
febrile granulocytopenic | 8 |
peptic ulcer | 8 |
expectorated sputum | 8 |
disease severity | 8 |
infectious diarrhea | 8 |
higher activity | 8 |
dental procedures | 8 |
throat swabs | 8 |
new antimicrobial | 8 |
raised without | 8 |
antibiotic access | 8 |
specific therapy | 7 |
affi nity | 7 |
united nations | 7 |
growth rate | 7 |
crystal structure | 7 |
predicted growth | 7 |
bacillus anthracis | 7 |
congestive heart | 7 |
epidemiological study | 7 |
identify patients | 7 |
care settings | 7 |
village pharmacies | 7 |
four times | 7 |
aetiologic diagnosis | 7 |
fecal contamination | 7 |
pneumococcal infections | 7 |
previous months | 7 |
hepatocellular carcinoma | 7 |
preventive medicine | 7 |
prediction rules | 7 |
objective criteria | 7 |
response rate | 7 |
longer courses | 7 |
high activity | 7 |
maxillary sinusitis | 7 |
antibiotic medicines | 7 |
control measures | 7 |
resistant acinetobacter | 7 |
preventive veterinary | 7 |
resistant microorganisms | 7 |
animal husbandry | 7 |
health systems | 7 |
different ecosystems | 7 |
antibiotics based | 7 |
elderly people | 7 |
significantly reduced | 7 |
effectiveness analysis | 7 |
veterinary practice | 7 |
reduced antibiotic | 7 |
research practice | 7 |
tlr signaling | 7 |
feed efficiency | 7 |
risk classes | 7 |
resistance profiles | 7 |
based study | 7 |
new derivatives | 7 |
pneumoniae infections | 7 |
urinary symptoms | 7 |
hospital waste | 7 |
antimicrobial activity | 7 |
double blind | 7 |
antibiotic drug | 7 |
study showed | 7 |
table shows | 7 |
surgical procedures | 7 |
new approaches | 7 |
term care | 7 |
flagellin amx | 7 |
clean water | 7 |
south africa | 7 |
husbandry practices | 7 |
internal medicine | 7 |
dairy calves | 7 |
significant decrease | 7 |
human services | 7 |
severe disease | 7 |
acquired infections | 7 |
individual patients | 7 |
pharmaceutical compounds | 7 |
highly effective | 7 |
personal communication | 7 |
oh group | 7 |
will provide | 7 |
acute pharyngotonsillitis | 7 |
ssi rate | 7 |
carrier state | 7 |
dna sequences | 7 |
pcr testing | 7 |
health perspective | 7 |
comparing antibiotic | 7 |
microscopic examination | 7 |
study found | 7 |
negative organisms | 7 |
respiratory symptoms | 7 |
rational use | 7 |
patients infected | 7 |
positive bacterial | 7 |
whole genome | 7 |
also used | 7 |
childhood asthma | 7 |
unknown origin | 7 |
office visits | 7 |
available data | 7 |
american college | 7 |
antiviral agents | 7 |
genetic exchange | 7 |
central line | 7 |
prospective observational | 7 |
tetracycline resistance | 7 |
clinical relevance | 7 |
care testing | 7 |
molecular biology | 7 |
demographic surveillance | 7 |
fluoroquinolone antibiotics | 7 |
pneumonia requiring | 7 |
position paper | 7 |
cattle vets | 7 |
antibiotic classes | 7 |
top three | 7 |
appropriate antibiotics | 7 |
expert group | 7 |
management decisions | 7 |
appropriate antimicrobial | 7 |
person transmission | 7 |
dairy farms | 7 |
cranberry products | 7 |
business model | 7 |
consensus guidelines | 7 |
risks associated | 7 |
watchful waiting | 7 |
significant effect | 7 |
course therapy | 7 |
cure rates | 7 |
healthcare professionals | 7 |
growth promoters | 7 |
individual health | 7 |
high level | 7 |
many years | 7 |
multivariate analysis | 7 |
mass spectrometry | 7 |
also contribute | 7 |
new zealand | 7 |
mouse model | 7 |
dna gyrase | 7 |
treating acute | 7 |
hpv infection | 7 |
human metapneumovirus | 7 |
clinical improvement | 7 |
common pathogens | 7 |
critical role | 7 |
dose therapy | 7 |
sectional study | 7 |
antibiotics will | 7 |
developing world | 7 |
antibiotics without | 7 |
amylase inhibitors | 7 |
purulent nasal | 7 |
gene sequencing | 7 |
unexplained fever | 7 |
testing may | 7 |
urine dipstick | 7 |
abacus project | 7 |
primary treatment | 7 |
human disease | 7 |
worth noting | 7 |
topoisomerase iv | 7 |
potential role | 7 |
randomised trial | 7 |
gram negative | 7 |
small number | 7 |
potential benefit | 7 |
project team | 7 |
chlamydia trachomatis | 7 |
vaccination coverage | 7 |
microbial community | 7 |
last resort | 7 |
environmental conditions | 7 |
broad range | 7 |
polyene macrolides | 7 |
chlamydia infection | 7 |
health concern | 7 |
therapy may | 7 |
bla oxa | 7 |
tlr agonist | 7 |
young adults | 7 |
inflammatory response | 7 |
acute sore | 7 |
cells mm | 7 |
clinical disease | 7 |
clinical outcome | 7 |
starting antibiotics | 7 |
chemical classes | 7 |
infections include | 7 |
wound infections | 7 |
group discussions | 7 |
monoclonal antibody | 7 |
uncomplicated uti | 7 |
randomized study | 7 |
amoxicillin clavulanate | 7 |
clinical symptoms | 7 |
clinical response | 7 |
recent antibiotic | 7 |
named conditions | 7 |
intestinal microbiota | 7 |
clinical evaluation | 7 |
amr scenario | 7 |
may increase | 7 |
animal models | 7 |
per inhabitants | 7 |
diseases specialist | 7 |
societal costs | 7 |
peptide core | 7 |
hospital settings | 7 |
chlamydophila pneumoniae | 7 |
microbial resistance | 7 |
adults aged | 7 |
several weeks | 7 |
uti management | 7 |
infected patients | 7 |
acute maxillary | 7 |
cell envelopes | 7 |
bronchoalveolar lavage | 7 |
pcr assay | 7 |
pneumococcal vaccination | 7 |
risk class | 7 |
diagnostic test | 7 |
cancer center | 7 |
cell line | 7 |
allergic rhinitis | 7 |
become infected | 7 |
accurate diagnosis | 7 |
uncomplicated abrs | 7 |
cfu ml | 7 |
test results | 7 |
tumour cells | 7 |
carboxyl group | 7 |
antibiotic costs | 7 |
clinical care | 6 |
will discuss | 6 |
resistance may | 6 |
described previously | 6 |
major global | 6 |
case management | 6 |
treatment technologies | 6 |
serious bacterial | 6 |
negative staphylococci | 6 |
antifungal agents | 6 |
prognostic factors | 6 |
hospital effluent | 6 |
central venous | 6 |
planetary health | 6 |
chemotherapeutic agents | 6 |
urgent need | 6 |
physicians often | 6 |
nearly years | 6 |
specific urti | 6 |
specific pathogens | 6 |
drug design | 6 |
chronic sinusitis | 6 |
pneumonia due | 6 |
early childhood | 6 |
inhibitory concentrations | 6 |
growth factor | 6 |
treating infections | 6 |
death rate | 6 |
different countries | 6 |
major public | 6 |
enteric viruses | 6 |
risk groups | 6 |
higher secondary | 6 |
clinical characteristics | 6 |
stranded rna | 6 |
closely related | 6 |
positive organisms | 6 |
strand breaks | 6 |
incubation period | 6 |
combating antibiotic | 6 |
interquartile range | 6 |
growth values | 6 |
hospital medical | 6 |
pneumoniae pneumonia | 6 |
care services | 6 |
several decades | 6 |
oral medication | 6 |
cdi recurrence | 6 |
authors declare | 6 |
coli bacteraemia | 6 |
pain relief | 6 |
different antibiotic | 6 |
retrospective studies | 6 |
ar transmission | 6 |
treat patients | 6 |
care units | 6 |
alexander fleming | 6 |
population level | 6 |
injection drug | 6 |
borrelia burgdorferi | 6 |
fire brigade | 6 |
persistent fever | 6 |
study population | 6 |
atypical pneumonia | 6 |
positive results | 6 |
first reported | 6 |
negative effects | 6 |
healthcare sector | 6 |
took place | 6 |
consensus report | 6 |
serologic testing | 6 |
higher mortality | 6 |
target bacteria | 6 |
human development | 6 |
normal science | 6 |
hydroxyl groups | 6 |
hospital admissions | 6 |
supply chains | 6 |
easy access | 6 |
recent systematic | 6 |
persisters formation | 6 |
foot infection | 6 |
microbiology laboratories | 6 |
food supply | 6 |
negative rods | 6 |
will need | 6 |
symptoms may | 6 |
respiratory secretions | 6 |
pneumonia severity | 6 |
likelihood ratio | 6 |
will develop | 6 |
amx alone | 6 |
common among | 6 |
developing new | 6 |
common practice | 6 |
environmental factors | 6 |
currently available | 6 |
phase iii | 6 |
hospital mortality | 6 |
times higher | 6 |
sewage treatment | 6 |
dental practices | 6 |
cell lysis | 6 |
health threat | 6 |
oxygen species | 6 |
results showed | 6 |
novel drug | 6 |
evaluate whether | 6 |
clinical assessment | 6 |
response rates | 6 |
producing bacteria | 6 |
prescribing guidance | 6 |
rhinovirus infections | 6 |
antibiotic failure | 6 |
veterinary practices | 6 |
rural vietnam | 6 |
large part | 6 |
clinically diagnosed | 6 |
early diagnosis | 6 |
surveillance data | 6 |
treated mice | 6 |
new antibacterial | 6 |
infection rates | 6 |
water treatment | 6 |
use may | 6 |
global problem | 6 |
human societies | 6 |
molecular docking | 6 |
gp practices | 6 |
empirical regimen | 6 |
bacterial aetiology | 6 |
many studies | 6 |
persistent cough | 6 |
secondary infections | 6 |
contaminated food | 6 |
significantly lower | 6 |
international trade | 6 |
quadruple therapy | 6 |
conjugative elements | 6 |
genital chlamydia | 6 |
knowledge gaps | 6 |
new cases | 6 |
bacterial cells | 6 |
weight gain | 6 |
cancer screening | 6 |
domestic animals | 6 |
symbiotic microbes | 6 |
clinical benefit | 6 |
antibiotic sales | 6 |
pseudomembranous colitis | 6 |
uti diagnostic | 6 |
frequently used | 6 |
crp levels | 6 |
dual therapy | 6 |
liver biopsy | 6 |
host range | 6 |
spectrum antibacterial | 6 |
days lost | 6 |
palm sap | 6 |
positive viral | 6 |
acute onset | 6 |
early life | 6 |
treat bacterial | 6 |
mortality associated | 6 |
one hand | 6 |
nasal congestion | 6 |
cell membranes | 6 |
metabolic pathways | 6 |
serum procalcitonin | 6 |
sample size | 6 |
nhs dental | 6 |
patients will | 6 |
id fellows | 6 |
pk pd | 6 |
aureus infection | 6 |
eustachian tube | 6 |
streptococcal ap | 6 |
acute viral | 6 |
also occur | 6 |
genes encoding | 6 |
molecular detection | 6 |
diagnostic accuracy | 6 |
commonly prescribed | 6 |
cochrane database | 6 |
cre infections | 6 |
prevention strategies | 6 |
treatment group | 6 |
acid synthesis | 6 |
dairy cattle | 6 |
extensively drug | 6 |
foodborne disease | 6 |
hib vaccine | 6 |
ultimate mechanism | 6 |
emerging diseases | 6 |
side chain | 6 |
multiple antibiotics | 6 |
surgical debridement | 6 |
one antibiotic | 6 |
diagnostic criteria | 6 |
also help | 6 |
subgroup analysis | 6 |
haemolytic streptococcus | 6 |
among older | 6 |
lung innate | 6 |
insertion sequences | 6 |
active tb | 6 |
intranasal flagellin | 6 |
maxillary sinus | 6 |
commensal bacteria | 6 |
future studies | 6 |
viral pcr | 6 |
different species | 6 |
enteric bacteria | 6 |
amino sugar | 6 |
lactam resistance | 6 |
haemolytic streptococci | 6 |
nasopharyngeal swab | 6 |
york city | 6 |
cause mortality | 6 |
many different | 6 |
health infrastructure | 6 |
difficile diarrhea | 6 |
life threatening | 6 |
evidence suggests | 6 |
retrospective study | 6 |
clinical microbiology | 6 |
acute infectious | 6 |
hydroxyl group | 6 |
gut microbes | 6 |
i need | 6 |
considered compliant | 6 |
major risk | 6 |
synthetic analogues | 6 |
marrow transplantation | 6 |
animal medicine | 6 |
clinical laboratory | 6 |
behaviour change | 6 |
treatment strategies | 6 |
common reasons | 6 |
clinically significant | 6 |
new targets | 6 |
aureus bacteremia | 6 |
cause disease | 6 |
binding site | 6 |
support systems | 6 |
antibiotics including | 6 |
susceptible strains | 6 |
performed using | 6 |
vitro susceptibility | 6 |
candida species | 6 |
categorical variables | 6 |
severely ill | 6 |
sector employment | 6 |
one every | 6 |
illnesses conditions | 6 |
one group | 6 |
every year | 6 |
viral uri | 6 |
methicillinresistant staphylococcus | 6 |
patients might | 6 |
great deal | 6 |
antibiotics within | 6 |
medical tourism | 6 |
less expensive | 6 |
natural product | 6 |
mdr gram | 6 |
diseases caused | 6 |
pseudomonas species | 6 |
tonsillar exudates | 6 |
coli isolates | 6 |
prudent use | 6 |
past two | 6 |
serious threat | 6 |
two thirds | 6 |
first line | 6 |
enterococcus faecalis | 6 |
widely available | 6 |
management guidelines | 6 |
pathogens including | 6 |
one half | 6 |
chronic hbv | 6 |
effective antibiotics | 6 |
genital warts | 6 |
saharan africa | 6 |
enteric disease | 6 |
therapy will | 6 |
public authorities | 6 |
farm animals | 6 |
tissue infection | 6 |
weight loss | 6 |
health approach | 6 |
blood samples | 6 |
published guidelines | 6 |
membrane proteins | 6 |
reduce unnecessary | 6 |
least two | 6 |
nasopharyngeal swabs | 6 |
long term | 6 |
significant difference | 6 |
human body | 6 |
synthetic compounds | 6 |
recently published | 6 |
bacteria isolated | 6 |
sustainable development | 6 |
medicated milk | 6 |
hematopoietic stem | 6 |
sudden onset | 6 |
global spread | 6 |
significant improvement | 6 |
nosocomial pathogens | 6 |
study reported | 6 |
three different | 6 |
groups indicated | 6 |
emergency departments | 6 |
acid amplification | 6 |
may develop | 6 |
clinical criteria | 6 |
commonly detected | 6 |
resistant enterococcus | 6 |
reactive oxygen | 6 |
care providers | 6 |
cost effectiveness | 6 |
viral replication | 6 |
medical school | 6 |
significantly higher | 6 |
opportunistic infections | 6 |
allowed us | 6 |
klebsiella pneumonia | 6 |
cell transplant | 6 |
well tolerated | 6 |
may decrease | 6 |
initial management | 6 |
small benefit | 6 |
healthcare epidemiology | 6 |
among bacterial | 6 |
low levels | 6 |
important cause | 6 |
food production | 6 |
care test | 6 |
sp strain | 6 |
clinical medicine | 6 |
microbial evolution | 6 |
clinical deterioration | 6 |
adult cattle | 6 |
treat acute | 6 |
functional groups | 6 |
synthetic antibiotics | 6 |
parenteral therapy | 6 |
care excellence | 6 |
dna damage | 6 |
cystitis sachets | 6 |
currently recommended | 6 |
number needed | 6 |
well known | 6 |
bla ctx | 6 |
infective drugs | 6 |
genetic engineering | 6 |
treating physician | 6 |
mediated immunity | 6 |
pylori resistance | 6 |
adverse reactions | 6 |
antibiotic coverage | 6 |
hygiene promotion | 6 |
necrotizing fasciitis | 6 |
animal species | 6 |
pulmonary tb | 6 |
flagellin flic | 5 |
next years | 5 |
healthy children | 5 |
care systems | 5 |
minor groove | 5 |
children younger | 5 |
society consensus | 5 |
first dose | 5 |
control groups | 5 |
significantly reduce | 5 |
plus either | 5 |
virus disease | 5 |
microbial populations | 5 |
breast cancer | 5 |
high prevalence | 5 |
neutrophil count | 5 |
ct scan | 5 |
spectrum drug | 5 |
indicator bacteria | 5 |
current guidelines | 5 |
aspergillus species | 5 |
adverse outcomes | 5 |
ssi workgroup | 5 |
infect dis | 5 |
evidence supporting | 5 |
important causes | 5 |
early treatment | 5 |
positive pathogens | 5 |
health research | 5 |
ed visits | 5 |
detection methods | 5 |
lower rtis | 5 |
recent advances | 5 |
pneumococcal meningitis | 5 |
bismuth quadruple | 5 |
clinical manifestations | 5 |
environmental pollution | 5 |
bronchopulmonary aspergillosis | 5 |
foodborne pathogens | 5 |
patients present | 5 |
industrial veterinary | 5 |
important antimicrobial | 5 |
using molecular | 5 |
cardiovascular disease | 5 |
dipstick results | 5 |
empirical coverage | 5 |
fungal disease | 5 |
chronic liver | 5 |
brain abscess | 5 |
lrti patients | 5 |
young people | 5 |
potential use | 5 |
high specificity | 5 |
trial comparing | 5 |
selection pressures | 5 |
randomized double | 5 |
mg po | 5 |
make better | 5 |
may account | 5 |
early administration | 5 |
associated teichoic | 5 |
pathogens present | 5 |
previous treatment | 5 |
greater risk | 5 |
another approach | 5 |
treatment regimens | 5 |
level monitoring | 5 |
clinical management | 5 |
although many | 5 |
oral mucositis | 5 |
institut pasteur | 5 |
chronic disease | 5 |
lactam ring | 5 |
use urine | 5 |
received amoxicillin | 5 |
eradication therapies | 5 |
continuous variables | 5 |
tested positive | 5 |
converting enzyme | 5 |
survival rate | 5 |
salmonella enterica | 5 |
sample sizes | 5 |
immune globulin | 5 |
lung injury | 5 |
combat antimicrobial | 5 |
abdominal infections | 5 |
preschool children | 5 |
antibiotic research | 5 |
pneumoniae isolates | 5 |
much greater | 5 |
acute infection | 5 |
close contacts | 5 |
acute influenza | 5 |
testicular cancer | 5 |
may reduce | 5 |
stewardship principles | 5 |
often associated | 5 |
theoretical domains | 5 |
oral intake | 5 |
specific treatment | 5 |
case series | 5 |
domains framework | 5 |
emergency medicine | 5 |
close contact | 5 |
binax now | 5 |
receive antibiotics | 5 |
organ failure | 5 |
antifungal resistance | 5 |
care setting | 5 |
daily doses | 5 |
etiologic agent | 5 |
inclusion criteria | 5 |
travel history | 5 |
included patients | 5 |
placebo groups | 5 |
might reduce | 5 |
likely pathogen | 5 |
months postintervention | 5 |
microbiota diversity | 5 |
disease emergence | 5 |
novel antibiotics | 5 |
intensive farming | 5 |
bacterial cystitis | 5 |
development goals | 5 |
varies according | 5 |
related adverse | 5 |
care medicine | 5 |
total antibiotic | 5 |
hygiene procedures | 5 |
negative bacteremia | 5 |
viral origin | 5 |
amx flagellin | 5 |
physical findings | 5 |
drugs used | 5 |
disease transmission | 5 |
swab culture | 5 |
vibrio vulnificus | 5 |
recent meta | 5 |
mrsa infection | 5 |
acquired bacterial | 5 |
cause severe | 5 |
streptococcal infections | 5 |
human antibiotic | 5 |
genome editing | 5 |
compared using | 5 |
clindamycin plus | 5 |
vitro studies | 5 |
significant risk | 5 |
diagnostic yield | 5 |
allergic bronchopulmonary | 5 |
failure rates | 5 |
lessons learned | 5 |
therapy group | 5 |
surveillance cultures | 5 |
prescribing practices | 5 |
initial improvement | 5 |
studies used | 5 |
outpatient care | 5 |
mild symptoms | 5 |
bacterial prostatitis | 5 |
preseptal cellulitis | 5 |
health approaches | 5 |
substrate binding | 5 |
drugs may | 5 |
genetic material | 5 |
isolation precautions | 5 |
hemorrhagic fever | 5 |
scientific community | 5 |
bowel preparation | 5 |
acute upper | 5 |
pseudomonas infection | 5 |
diagnostic methods | 5 |
clinical scores | 5 |
medical education | 5 |
statistical significance | 5 |
care staff | 5 |
wicked problem | 5 |
facial pain | 5 |
major problem | 5 |
health problems | 5 |
particularly important | 5 |
major challenge | 5 |
one year | 5 |
grade fever | 5 |
great interest | 5 |
influenza vaccines | 5 |
chronic respiratory | 5 |
health implications | 5 |
vaccination uptake | 5 |
soil bacteria | 5 |
biological properties | 5 |
antibiotic choice | 5 |
patient presents | 5 |
health concerns | 5 |
digestive decontamination | 5 |
opportunistic pathogens | 5 |
many antibiotics | 5 |
organ transplant | 5 |
colonization resistance | 5 |
primary syphilis | 5 |
antibacterial drugs | 5 |
local susceptibility | 5 |
prescribing rates | 5 |
directed therapy | 5 |
new molecular | 5 |
resistance threats | 5 |
gene cassettes | 5 |
informed consent | 5 |
laboratory findings | 5 |
fatty acid | 5 |
carbohydrate chains | 5 |
hybrid antibiotics | 5 |
eradication regimens | 5 |
fda approved | 5 |
health must | 5 |
also associated | 5 |
local antibiotic | 5 |
mammalian cells | 5 |
pneumocystis carinii | 5 |
new host | 5 |
chemical modifications | 5 |
best practices | 5 |
related infections | 5 |
microbiota transplant | 5 |
narrow spectrum | 5 |
bacterial ap | 5 |
elderly persons | 5 |
also may | 5 |
organ transplantation | 5 |
children years | 5 |
higher risk | 5 |
recent clinical | 5 |
pelvic pain | 5 |
increasingly important | 5 |
digestive tract | 5 |
international antimicrobial | 5 |
ambulatory antibiotic | 5 |
receive either | 5 |
long periods | 5 |
also increased | 5 |
diabetes mellitus | 5 |
pilot study | 5 |
site infections | 5 |
global public | 5 |
chemically synthesized | 5 |
new antimicrobials | 5 |
human infections | 5 |
swollen anterior | 5 |
lactam agents | 5 |
provider knowledge | 5 |
carbapenem resistance | 5 |
rheumatoid arthritis | 5 |
microbial pathogens | 5 |
aspergillus niger | 5 |
topoisomerase ii | 5 |
dental care | 5 |
ambulatory patients | 5 |
antibiotic changes | 5 |
penicillin resistance | 5 |
invasive candidiasis | 5 |
infection among | 5 |
therapeutic levels | 5 |
potential impact | 5 |
cause infections | 5 |
cellular immunity | 5 |
severe infection | 5 |
per liter | 5 |
various infectious | 5 |
municipal wastewater | 5 |
severe symptoms | 5 |
systemic toxicity | 5 |
clinical data | 5 |
community pharmacy | 5 |
asia pacific | 5 |
surveillance programme | 5 |
mic breakpoints | 5 |
information regarding | 5 |
macrolide alone | 5 |
world war | 5 |
will continue | 5 |
empiric treatment | 5 |
environmental surfaces | 5 |
therapeutic outcome | 5 |
effective therapy | 5 |
management practices | 5 |
water quality | 5 |
doubly modified | 5 |
mortality due | 5 |
help reduce | 5 |
laboratory testing | 5 |
take oral | 5 |
susceptibility patterns | 5 |
intranasal instillation | 5 |
soviet union | 5 |
th century | 5 |
preferred treatment | 5 |
acute osteomyelitis | 5 |
local health | 5 |
frequently associated | 5 |
recent examples | 5 |
discuss antibiotic | 5 |
first days | 5 |
rapid test | 5 |
threatening infections | 5 |
blood count | 5 |
influenza pneumonia | 5 |
difficile colitis | 5 |
may reveal | 5 |
respiratory hygiene | 5 |
passive transfer | 5 |
supportive care | 5 |
antitumour agents | 5 |
susceptible bacteria | 5 |
severe cases | 5 |
global solutions | 5 |
acute lower | 5 |
hematological malignancy | 5 |
global climate | 5 |
dengue fever | 5 |
nosocomial infections | 5 |
postoperative wound | 5 |
type iv | 5 |
orbital complications | 5 |
treatment decisions | 5 |
international organizations | 5 |
may even | 5 |
increased use | 5 |
domestic sales | 5 |
blind studies | 5 |
causative agents | 5 |
body weight | 5 |
condition ranking | 5 |
guideline implementation | 5 |
medical records | 5 |
wall synthesis | 5 |
chemical libraries | 5 |
highly pathogenic | 5 |
erythromycin resistance | 5 |
influenza antiviral | 5 |
years later | 5 |
dna breaks | 5 |
studies suggest | 5 |
ar problem | 5 |
lateral gene | 5 |
economic burden | 5 |
low concentration | 5 |
fold higher | 5 |
tackle ar | 5 |
risk stratification | 5 |
fatty acids | 5 |
improve antibiotic | 5 |
water systems | 5 |
tandem mass | 5 |
directly related | 5 |
health risk | 5 |
high frequency | 5 |
bactericidal action | 5 |
phase i | 5 |
etiologic agents | 5 |
less toxic | 5 |
common illnesses | 5 |
resistant gene | 5 |
tick bite | 5 |
prospective randomized | 5 |
acquired methicillin | 5 |
recurrent utis | 5 |
active effl | 5 |
improve outcomes | 5 |
total number | 5 |
antibiotics resistance | 5 |
immunization practices | 5 |
treatment systems | 5 |
common infection | 5 |
water sources | 5 |
acute infections | 5 |
tract complications | 5 |
alkaline hydrolysis | 5 |
antiviral therapy | 5 |
enterobacteriaceae species | 5 |
disaccharide branch | 5 |
inspection service | 5 |
resistance potential | 5 |
rrn operons | 5 |
healthy volunteers | 5 |
new ways | 5 |
general public | 5 |
drug companies | 5 |
potential pathogens | 5 |
finding new | 5 |
medical research | 5 |
persisting fever | 5 |
need antibiotics | 5 |
secondary outcomes | 5 |
uk national | 5 |
cell transplantation | 5 |
resistance determinant | 5 |
important factor | 5 |
cervical cancer | 5 |
chronic diseases | 5 |
label claims | 5 |
phase ii | 5 |
resistant pneumococci | 5 |
without treatment | 5 |
often used | 5 |
continuation phase | 5 |
resistance problem | 5 |
potential adverse | 5 |
hospitalized children | 5 |
chemotherapeutic regimens | 5 |
new classes | 5 |
relevant outcomes | 5 |
pathogens without | 5 |
ar dissemination | 5 |
tracheal aspirate | 5 |
frequently prescribed | 5 |
anthony fauci | 5 |
may benefit | 5 |
prophylactic use | 5 |
target group | 5 |
antibacterial therapy | 5 |
new hiv | 5 |
teichoic acid | 5 |
disseminated gonococcal | 5 |
aureolic acid | 5 |
one hundred | 5 |
findings may | 5 |
therapeutic strategies | 5 |
penicillin allergy | 5 |
small molecule | 5 |
support tools | 5 |
factors influencing | 5 |
detection tests | 5 |
foreign dna | 5 |
four criteria | 5 |
resistant mutants | 5 |
commercially available | 5 |
cell growth | 5 |
another example | 5 |
rural bangladesh | 5 |
collateral sensitivity | 5 |
related compounds | 5 |
status changes | 5 |
project goal | 5 |
drug target | 5 |
molecular point | 5 |
first report | 5 |
lung infection | 5 |
gastrointestinal tract | 5 |
medical conditions | 5 |
department visits | 5 |
necrotizing pneumonia | 5 |
successfully treated | 5 |
antibody response | 5 |
studies also | 5 |
lactamase genes | 5 |
resistant mycoplasma | 5 |
resistant clinical | 5 |
health statistics | 5 |
study using | 5 |
new anti | 5 |
target population | 5 |
molecular weight | 5 |
older patients | 5 |
urban wastewater | 5 |
quite different | 5 |
mm hg | 5 |
ebola virus | 5 |
outpatient therapy | 5 |
per animal | 5 |
bacterial cultures | 5 |
treated group | 5 |
collateral damage | 5 |
selective digestive | 5 |
may change | 5 |
complicated intra | 5 |
left untreated | 5 |
beneficial effect | 5 |
febrile illness | 5 |
see supplementary | 5 |
nipah virus | 5 |
clinical examination | 5 |
medical practice | 5 |
hospital care | 5 |
patients undergoing | 5 |
chest radiographs | 5 |
make sure | 5 |
east asia | 5 |
sample frame | 5 |
fever accompanied | 5 |
gramnegative bacteria | 5 |
will include | 5 |
economic growth | 5 |
treating influenza | 5 |
critical care | 5 |
inflammatory responses | 5 |
nasal drainage | 5 |
infectious agent | 5 |
clinical impact | 5 |
among others | 5 |
asthma development | 5 |
hybrid structures | 5 |
support resources | 5 |
bacterial superinfection | 5 |
longer duration | 5 |
microbiologically documented | 5 |
divided doses | 5 |
high doses | 5 |
infected cells | 5 |
human activities | 5 |
general hospital | 5 |
increase awareness | 5 |
decrease ssis | 5 |
chronic pulmonary | 5 |
major driver | 5 |
us food | 5 |
nabh cn | 5 |
widely accepted | 5 |
animal food | 5 |
cervical lymphadenopathy | 5 |
polymyxin resistance | 5 |
results show | 5 |
normal flora | 5 |
protecting group | 5 |
several days | 5 |
serious complications | 5 |
small sample | 5 |
east respiratory | 5 |
may limit | 5 |
defense system | 5 |
common clinical | 5 |
antibiotics sha | 5 |
longer period | 5 |
cause infection | 5 |
orbital abscess | 5 |
relatively short | 5 |
prospective cohort | 5 |
cell envelope | 5 |
increased incidence | 5 |
north trinidad | 5 |
early antibiotic | 5 |
care center | 5 |
fluid resuscitation | 5 |
aap aafp | 4 |
jurisdictional claims | 4 |
may vary | 4 |
aquatic ecosystems | 4 |
big data | 4 |
uncomplicated cases | 4 |
economic incentives | 4 |
febrile episodes | 4 |
publication bias | 4 |
quantitative microbial | 4 |
water environment | 4 |
infected patient | 4 |
clinical judgment | 4 |
bacterial genomes | 4 |
early clinical | 4 |
positive likelihood | 4 |
also considered | 4 |
ebola outbreak | 4 |
rural areas | 4 |
molecular analysis | 4 |
infectious particles | 4 |
healthcare associated | 4 |
icu care | 4 |
low sensitivity | 4 |
negative bacterial | 4 |
patient education | 4 |
low prevalence | 4 |
peptidoglycan synthesis | 4 |
quick reference | 4 |
first generation | 4 |
might help | 4 |
pcr method | 4 |
synthesized based | 4 |
million cases | 4 |
prospective validation | 4 |
pathogens isolated | 4 |
oral cephalosporins | 4 |
cause pharyngotonsillitis | 4 |
homology modeling | 4 |
related mortality | 4 |
human intestinal | 4 |
appropriate therapy | 4 |
older children | 4 |
comprehensive antibiotic | 4 |
interventions may | 4 |
antibiotic abuse | 4 |
zika virus | 4 |
near patient | 4 |
detected viruses | 4 |
protease inhibitors | 4 |
require hospital | 4 |
one trial | 4 |
previously reported | 4 |
bacterial cause | 4 |
tuberculosis infection | 4 |
last decade | 4 |
starting compound | 4 |
fungal strains | 4 |
odds ratios | 4 |
suppurative otitis | 4 |
inhibitory effects | 4 |
different settings | 4 |
improvement program | 4 |
needle aspiration | 4 |
whooping cough | 4 |
war ii | 4 |
fourth generation | 4 |
uncomplicated upper | 4 |
antibiotic utilization | 4 |
will result | 4 |
animal veterinary | 4 |
studies performed | 4 |
veterinary drug | 4 |
folic acid | 4 |
studies showing | 4 |
nice guideline | 4 |
poultry production | 4 |
pneumophila serogroup | 4 |
standard treatment | 4 |
home intravenous | 4 |
fusion protein | 4 |
per capita | 4 |
detailed analysis | 4 |
highly active | 4 |
european society | 4 |
liposomal amphotericin | 4 |
flow cytometry | 4 |
conditions illnesses | 4 |
within min | 4 |
health authorities | 4 |
certain antibiotics | 4 |
sedimentation rate | 4 |
positive pcr | 4 |
pooled standard | 4 |
million deaths | 4 |
noninfectious causes | 4 |
starting point | 4 |
antibiotics given | 4 |
national survey | 4 |
alternative diagnosis | 4 |
primary education | 4 |
studies evaluating | 4 |
significant clinical | 4 |
ultimate causes | 4 |
campylobacter spp | 4 |
emr alerts | 4 |
voluntary labeling | 4 |
often occurs | 4 |
pelvic inflammatory | 4 |
hospital setting | 4 |
new compounds | 4 |
use remains | 4 |
benefit must | 4 |
now recommended | 4 |
human respiratory | 4 |
intestinal flora | 4 |
significantly shorter | 4 |
high cost | 4 |
billion people | 4 |
specific conditions | 4 |
foodborne illness | 4 |
even among | 4 |
study conducted | 4 |
molecular poct | 4 |
antibacterial treatment | 4 |
year prospective | 4 |
limited information | 4 |
liver function | 4 |
parenteral antibiotics | 4 |
well understood | 4 |
negative results | 4 |
treatment outcome | 4 |
term impacts | 4 |
proteins involved | 4 |
high temperature | 4 |
cancer cell | 4 |
hav infection | 4 |
control study | 4 |
insufficient data | 4 |
important part | 4 |
relatively straightforward | 4 |
mutation based | 4 |
surveillance study | 4 |
years since | 4 |
one major | 4 |
facial pressure | 4 |
less frequently | 4 |
carinii pneumonia | 4 |
lactobacillus rhamnosus | 4 |
asthma risk | 4 |
weekly isoniazid | 4 |
rapid emergence | 4 |
lethal effects | 4 |
microbial risk | 4 |
nature remains | 4 |
pneumococcal vaccine | 4 |
therapy alone | 4 |
binding affinity | 4 |
intranasal administration | 4 |
van der | 4 |
proteus mirabilis | 4 |
chest pain | 4 |
clinical cure | 4 |
cdc estimates | 4 |
presentation will | 4 |
global report | 4 |
proper use | 4 |
toxic megacolon | 4 |
various types | 4 |
requiring vasopressors | 4 |
nontraditional therapies | 4 |
azithromycin alone | 4 |
ribosomal rna | 4 |
major role | 4 |
symptoms persist | 4 |
protein vp | 4 |
infection within | 4 |
prevention strategy | 4 |
cell count | 4 |
blood urea | 4 |
new analogues | 4 |
hidden costs | 4 |
secondary outcome | 4 |
resistance evolution | 4 |
animal bite | 4 |
amx pbs | 4 |
also called | 4 |
better informed | 4 |
bacterial endocarditis | 4 |
help inform | 4 |
national health | 4 |
persistent symptoms | 4 |
agents include | 4 |
second line | 4 |
may warrant | 4 |
symptoms including | 4 |
treat analysis | 4 |
mg four | 4 |
also increase | 4 |
analysis probiotics | 4 |
species including | 4 |
past decade | 4 |
infection society | 4 |
tonsillar exudate | 4 |
revised clsi | 4 |
patient will | 4 |
rrna gene | 4 |
farm groups | 4 |
telephone consultations | 4 |
year vision | 4 |
managing acute | 4 |
small animal | 4 |
symptom onset | 4 |
empiric regimen | 4 |
daytime cough | 4 |
clinical failure | 4 |
expiratory flow | 4 |
prescribing decisions | 4 |
antibiotics might | 4 |
reductive alkylation | 4 |
ed visit | 4 |
multicenter study | 4 |
molecular diagnostics | 4 |
reducing transmission | 4 |
high crp | 4 |
administered orally | 4 |
individual level | 4 |
infections globally | 4 |
depot form | 4 |
best way | 4 |
chronic cough | 4 |
sinus inflammation | 4 |
chinese journal | 4 |
originally isolated | 4 |
center study | 4 |
acutely ill | 4 |
molecular mechanisms | 4 |
days later | 4 |
used without | 4 |
fast bacilli | 4 |
time period | 4 |
rabx group | 4 |
type ii | 4 |
without symptoms | 4 |
practical use | 4 |
among inpatients | 4 |
large percentage | 4 |
mean duration | 4 |
carbapenem antibiotics | 4 |
chikungunya virus | 4 |
oral dexamethasone | 4 |
significant role | 4 |
increased understanding | 4 |
will probably | 4 |
frontal sinuses | 4 |
also identified | 4 |
point mutations | 4 |
effective antibiotic | 4 |
still needed | 4 |
oral flora | 4 |
pneumococcal respiratory | 4 |
food industry | 4 |
similar way | 4 |
alone may | 4 |
monthly evaluation | 4 |
uncomplicated utis | 4 |
respiratory illnesses | 4 |
rules laws | 4 |
antibiotic kills | 4 |
address antimicrobial | 4 |
commonly seen | 4 |
cancer cells | 4 |
host defense | 4 |
exposure prophylaxis | 4 |
one day | 4 |
authors concluded | 4 |
recurrent clostridium | 4 |
antiviral drugs | 4 |
genetically engineered | 4 |
clinical study | 4 |
communities present | 4 |
pulmonary function | 4 |
initial infection | 4 |
acute purulent | 4 |
cd pyrene | 4 |
peer review | 4 |
based clinical | 4 |
valentine leukocidin | 4 |
global antibiotic | 4 |
southeast asia | 4 |
enteric pathogens | 4 |
three recent | 4 |
national level | 4 |
generation sequencing | 4 |
endotracheal aspirates | 4 |
microbial etiology | 4 |
underlying lung | 4 |
responsible use | 4 |
renal insufficiency | 4 |
nasal polyps | 4 |
chemical transformations | 4 |
work together | 4 |
group compared | 4 |
international scientific | 4 |
diagnose group | 4 |
including influenza | 4 |
protective effect | 4 |